Synopsis
Synopsis
0
VMF
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Hydroxychlorochin
2. Hydroxychloroquine
3. Hydroxychloroquine Sulfate (1:1) Salt
4. Oxychlorochin
5. Oxychloroquine
6. Plaquenil
1. 747-36-4
2. Hydroxychloroquine Sulphate
3. Ercoquin
4. Plaquenil
5. 2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethanol Sulfate
6. Quensyl
7. Oxiklorin
8. Tcmdc-123987
9. Hcq Sulfate
10. Plaquenil Sulfate
11. Nsc 4375
12. Hydroxychloroquine (sulfate)
13. Oxichlorochine Sulfate
14. Nsc-4375
15. 8q2869cnvh
16. 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;sulfuric Acid
17. 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol; Sulfuric Acid
18. Plaquinol
19. Toremonil
20. 2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol Sulfate
21. Dsstox_cid_27788
22. Dsstox_rid_82563
23. N4-(7-chloro-4-quinolyl)-n1-ethyl-n1-(2-hydroxyethyl)-1,4-pentanediamine Sulfate
24. Dsstox_gsid_47811
25. 2-((4-(7-chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol Sulfate
26. 2-((4-((7-chloroquinolin-4-yl)amino)-pentyl)(ethyl)amino)ethanol Sulfate
27. Cas-747-36-4
28. Hydroxychloroquine Sulfate [usp]
29. Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-, Sulfate (1:1)
30. Sr-05000001881
31. Ncgc00159483-02
32. Einecs 212-019-3
33. Unii-8q2869cnvh
34. Quinoric
35. Ai3-52706
36. Plaquenil (tn)
37. Ethanol, Monosulfate
38. Mfcd00078203
39. Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-, Sulfate (1:1)
40. Hydroxychlorquine Sulfate
41. 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)ethanol Sulfate (1:1) (salt)
42. 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol Sulfate (1:1) (salt)
43. Chembl1690
44. Ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-, Sulfate (1:1) (salt)
45. Schembl41114
46. Spectrum1503978
47. 747-36-4 (sulfate)
48. Dtxsid1047811
49. Hydroxychloroquine Sulfate ,(s)
50. Hydroxychloroquine Sulfate- Bio-x
51. Ethanol, Sulfate (1:1) (salt)
52. Hms1922o12
53. Hms2093o05
54. Hms3713j22
55. Pharmakon1600-01503978
56. Bcp12823
57. Hy-b1370
58. Tox21_111707
59. Bdbm50247975
60. Ccg-39154
61. Nsc758663
62. S4430
63. Hydroxychloroquine Sulfate (jan/usp)
64. Akos015897337
65. Tox21_111707_1
66. Cs-8017
67. Hydroxychloroquine Sulfate [mi]
68. Ks-5311
69. Nsc-758663
70. Sb19140
71. (+-)-2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol Sulfate (1:1) (salt)
72. 7-chloro-4-[4-[n-ethyl-n-(2-hydroxyethyl)amino]-1-methylbutylamino]quinoline Sulfate
73. Hydroxychloroquine Sulfate [jan]
74. Ncgc00095090-01
75. Ncgc00095090-02
76. Ncgc00159483-04
77. Bh164525
78. Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethyl)amino-, (+-)-, Sulfate (1:1) Salt
79. Hydroxychloroquine Sulfate [mart.]
80. Hydroxychloroquine Sulfate [vandf]
81. Hydroxychloroquine Sulfate [usp-rs]
82. Hydroxychloroquine Sulfate [who-dd]
83. Db-055904
84. Ft-0603511
85. Ft-0669460
86. H1306
87. Hydroxycloroquine Sulfate, Analytical Standard
88. D02114
89. H10433
90. Hydroxychloroquine Sulfate [orange Book]
91. Hydroxychloroquine Sulfate [ep Monograph]
92. 747h364
93. A838213
94. Hydroxychloroquine Sulfate [usp Monograph]
95. Hydroxychloroquine Sulfate, >=98% (hplc), Powder
96. Sr-05000001881-1
97. Sr-05000001881-2
98. W-104413
99. Q27270879
100. Z1551900864
101. Hydroxychloroquine Sulphate 1.0 Mg/ml In Methanol (as Free Base)
102. 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]ethanol Sulfate
103. Hydroxychloroquine Sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
104. Hydroxychloroquine Sulfate, United States Pharmacopeia (usp) Reference Standard
105. (+/-)-2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol Sulfate (1:1) (salt)
106. (+/-)-2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol Sulphate (1:1) (salt)
107. 14480-75-2
108. Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethyl)amino-, (+/-)-, Sulfate (1:1) Salt
109. Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethyl)amino-, (+/-)-, Sulphate (1:1) Salt
Molecular Weight | 434.0 g/mol |
---|---|
Molecular Formula | C18H28ClN3O5S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 9 |
Exact Mass | 433.1438199 g/mol |
Monoisotopic Mass | 433.1438199 g/mol |
Topological Polar Surface Area | 131 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 413 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Hydroxychloroquine sulfate |
Drug Label | Hydroxychloroquine sulfate, USP is a colorless crystalline solid, soluble in water to at least 20 percent; chemically the drug is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino] ethanol sulfate (1:1). Hydroxychloroquine sulfate, USP has the fo... |
Active Ingredient | Hydroxychloroquine sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg |
Market Status | Prescription |
Company | Sandoz; Hikma Pharms; Teva Pharms; Ipca Labs; Zydus Pharms Usa; Mylan |
2 of 2 | |
---|---|
Drug Name | Hydroxychloroquine sulfate |
Drug Label | Hydroxychloroquine sulfate, USP is a colorless crystalline solid, soluble in water to at least 20 percent; chemically the drug is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino] ethanol sulfate (1:1). Hydroxychloroquine sulfate, USP has the fo... |
Active Ingredient | Hydroxychloroquine sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg |
Market Status | Prescription |
Company | Sandoz; Hikma Pharms; Teva Pharms; Ipca Labs; Zydus Pharms Usa; Mylan |
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
About the Company : EUROAPI is the market leader in small molecule APIs with projected sales of about €1 billion in 2022. With around 200 APIs, it has one of the largest portfolios in the market. Th...
About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...
About the Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class quality in the Midd...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
About the Company : Atman Pharma Private Limited is a fully integrated pharmaceutical company that has distinguished itself as a leader in Bulk Drugs (API) marketing both domestically in India and ove...
About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
About the Company : SCI Pharmtech Inc. offers APIs, advanced intermediates, and custom products, focusing on quick development and cost-effective production. Our research labs, pilot plants, and produ...
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
About the Company : Zeal MediPharma is a globally recognized Star One Export House, serving customers in over 50 countries for more than two decades. We specialize in sourcing and exporting high-quali...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Brand Name: IHL-675A
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Product Name : IHL-675A
Product Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2023
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Brand Name: IHL-675A
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Product Name : IHL-675A
Product Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2023
Details:
IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Brand Name: IHL-675A
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.
Product Name : IHL-675A
Product Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2023
Details:
IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Brand Name: IHL-675A
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Product Name : IHL-675A
Product Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2022
Details:
Codebase Ventures provided an update on the continued development of its proposed transdermal delivery technology for hydroxychloroquine (HCQ). The drug has been approved by the USFDA as a treatment against malaria, lupus, and rheumatoid arthritis.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Codebase Ventures provided an update on the continued development of its proposed transdermal delivery technology for hydroxychloroquine (HCQ). The drug has been approved by the USFDA as a treatment against malaria, lupus, and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2021
Details:
The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
Lead Product(s): Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Niagen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Lead Product(s) : Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L...
Product Name : Niagen
Product Type : Small molecule
Upfront Cash : Not Applicable
February 04, 2021
Details:
ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Apogenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Apogenix
Deal Size : Not Applicable
Deal Type : Not Applicable
COVID-19: Targeted Treatment Trial Launched in Vienna
Details : ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 22, 2020
Details:
Rafael Pharmaceuticals will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue, in partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC).
Lead Product(s): Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Brand Name: CPI-613
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Sara’s Cure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2020
Lead Product(s) : Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sara’s Cure
Deal Size : Undisclosed
Deal Type : Partnership
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Tri...
Details : Rafael Pharmaceuticals will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue, in partnership with Sara’s Cure and Sarcoma Alliance for Research through ...
Product Name : CPI-613
Product Type : Small molecule
Upfront Cash : Undisclosed
December 01, 2020
Details:
The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Lead Product(s): Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Inserm-ANRS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Lead Product(s) : Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inserm-ANRS
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2020
Details:
The finding suggest that hydroxychloroquine is not effective for the treatment of COVID-19 was consistent across patient subgroups and for all evaluated outcomes, including clinical status, mortality, organ failures, duration of oxygen use, and hospital length of stay.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NIH Reports that Hydroxychloroquine Does Not Benefit Adults Hospitalized With COVID-19
Details : The finding suggest that hydroxychloroquine is not effective for the treatment of COVID-19 was consistent across patient subgroups and for all evaluated outcomes, including clinical status, mortality, organ failures, duration of oxygen use, and hospital ...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
45
PharmaCompass offers a list of Hydroxychloroquine Sulphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hydroxychloroquine Sulphate manufacturer or Hydroxychloroquine Sulphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydroxychloroquine Sulphate manufacturer or Hydroxychloroquine Sulphate supplier.
PharmaCompass also assists you with knowing the Hydroxychloroquine Sulphate API Price utilized in the formulation of products. Hydroxychloroquine Sulphate API Price is not always fixed or binding as the Hydroxychloroquine Sulphate Price is obtained through a variety of data sources. The Hydroxychloroquine Sulphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Hydroxychloroquine Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hydroxychloroquine Sulfate, including repackagers and relabelers. The FDA regulates Hydroxychloroquine Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hydroxychloroquine Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hydroxychloroquine Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hydroxychloroquine Sulfate supplier is an individual or a company that provides Hydroxychloroquine Sulfate active pharmaceutical ingredient (API) or Hydroxychloroquine Sulfate finished formulations upon request. The Hydroxychloroquine Sulfate suppliers may include Hydroxychloroquine Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Hydroxychloroquine Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hydroxychloroquine Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Hydroxychloroquine Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Hydroxychloroquine Sulfate DMFs exist exist since differing nations have different regulations, such as Hydroxychloroquine Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hydroxychloroquine Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Hydroxychloroquine Sulfate USDMF includes data on Hydroxychloroquine Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hydroxychloroquine Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hydroxychloroquine Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hydroxychloroquine Sulfate Drug Master File in Japan (Hydroxychloroquine Sulfate JDMF) empowers Hydroxychloroquine Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hydroxychloroquine Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Hydroxychloroquine Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hydroxychloroquine Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Hydroxychloroquine Sulfate Drug Master File in Korea (Hydroxychloroquine Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hydroxychloroquine Sulfate. The MFDS reviews the Hydroxychloroquine Sulfate KDMF as part of the drug registration process and uses the information provided in the Hydroxychloroquine Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Hydroxychloroquine Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hydroxychloroquine Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Hydroxychloroquine Sulfate suppliers with KDMF on PharmaCompass.
A Hydroxychloroquine Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Hydroxychloroquine Sulfate Certificate of Suitability (COS). The purpose of a Hydroxychloroquine Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hydroxychloroquine Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hydroxychloroquine Sulfate to their clients by showing that a Hydroxychloroquine Sulfate CEP has been issued for it. The manufacturer submits a Hydroxychloroquine Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hydroxychloroquine Sulfate CEP holder for the record. Additionally, the data presented in the Hydroxychloroquine Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hydroxychloroquine Sulfate DMF.
A Hydroxychloroquine Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hydroxychloroquine Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hydroxychloroquine Sulfate suppliers with CEP (COS) on PharmaCompass.
A Hydroxychloroquine Sulfate written confirmation (Hydroxychloroquine Sulfate WC) is an official document issued by a regulatory agency to a Hydroxychloroquine Sulfate manufacturer, verifying that the manufacturing facility of a Hydroxychloroquine Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hydroxychloroquine Sulfate APIs or Hydroxychloroquine Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Hydroxychloroquine Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Hydroxychloroquine Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hydroxychloroquine Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hydroxychloroquine Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hydroxychloroquine Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hydroxychloroquine Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hydroxychloroquine Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hydroxychloroquine Sulfate suppliers with NDC on PharmaCompass.
Hydroxychloroquine Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hydroxychloroquine Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hydroxychloroquine Sulfate GMP manufacturer or Hydroxychloroquine Sulfate GMP API supplier for your needs.
A Hydroxychloroquine Sulfate CoA (Certificate of Analysis) is a formal document that attests to Hydroxychloroquine Sulfate's compliance with Hydroxychloroquine Sulfate specifications and serves as a tool for batch-level quality control.
Hydroxychloroquine Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Hydroxychloroquine Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hydroxychloroquine Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Hydroxychloroquine Sulfate EP), Hydroxychloroquine Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hydroxychloroquine Sulfate USP).